MA
ORMP icon

MCF Advisors’s Oramed Pharmaceuticals ORMP Stock Holding History

MCF Advisors’s Portfolio ORMP Stock Details ORMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.16K Buy
+1,073
New +$4.27K ﹤0.01% 1153

Other funds holding ORMP

Mercer Global Advisors
Mercer Global Advisors Denver, Colorado $80.9B AUM 26.08% 1-Year Est. Return
AF
Aquamarine Financial George Town $1.81B AUM 38.21% 1-Year Est. Return
GIA
Gem Investment Advisors Teaneck, New Jersey $163M AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
M
Murchinson Toronto, Ontario, Canada $725M AUM 82.02% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

MCF Advisors's ORMP Position: Q2 2026 in Review

MCF Advisors opened a new position in Oramed Pharmaceuticals (ORMP) in Q2 2026: 1,073 shares worth $5.16K. The stake represents ﹤0.01% of the portfolio and ranks #1153 among its holdings.

84 funds tracked by Wall St. Rank hold ORMP as of Q2 2026.

  • MCF Advisors held 1,073 shares of Oramed Pharmaceuticals worth $5.16K as of Q2 2026.
  • Oramed Pharmaceuticals was a new MCF Advisors position in Q2 2026.
  • Oramed Pharmaceuticals made up ﹤0.01% of MCF Advisors's portfolio in Q2 2026, its #1153 holding.
  • 84 funds tracked by Wall St. Rank held Oramed Pharmaceuticals as of Q2 2026.

Based on MCF Advisors's 13F filing for Q2 2026, filed 12 Aug 2026.